
Feb 23 (Reuters) - Protara Therapeutics Inc TARA.O:
TARA-002 DEMONSTRATES 68% COMPLETE RESPONSE RATE AT SIX MONTHS IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
PROTARA THERAPEUTICS INC: EXPECTS TO COMPLETE ENROLLMENT OF BCG-UNRESPONSIVE COHORT OF ADVANCED-2 TRIAL IN 2H 2026
PROTARA THERAPEUTICS INC: FAVORABLE SAFETY AND TOLERABILITY PROFILE WITH NO GRADE 3 OR GREATER TREATMENT-RELATED ADVERSE EVENTS
PROTARA THERAPEUTICS INC: REMAINS ON TRACK TO INITIATE ADVANCED-3 REGISTRATIONAL TRIAL IN BCG-NAÏVE PATIENTS IN SECOND HALF OF 2026